Below is a look at some of the headlines for companies that made news in the healthcare sector on September 29, 2011.
Shares of Edwards Lifesciences (NYSE:EW) dropped by more than 7% Thursday as the Centers for Medicare and Medicaid Services dampened enthusiasm over the medical device maker's Sapien catheter-delivered heart valve.
CMS said on Wednesday it was conducting an analysis on devices like Sapien that are still in the testing stage. JPMorgan analyst Michael Weinstein said in a note to clients that CMS may restrict early adoption of the device, thus putting a crimp on Edwards' sales in future years.
Boston Scientific Corp. (NYSE:BSX) announced the U.S. Court of Appeals for the Federal Circuit found in favor of the Company in a 1998 patent infringement suit involving Johnson & Johnson. In the decision, the Court of Appeals affirmed the U.S. District Court for the District of Delaware decision finding that Boston Scientific's NIR Stent did not infringe Johnson & Johnson's Fischell patent.
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, announced the availability of a new video featuring Marc D. Beer, Chief Executive Officer of Aegerion, discussing business strategy and objectives related to the company’s lead product candidate, lomitapide.
Biogen Idec (NASDAQ: BIIB) today announced that Tony Kingsley has been promoted to Executive Vice President, Global Commercial Operations, effective Nov. 7.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 27, at 5:00 p.m. ET to discuss third quarter 2011 financial results.
BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the 2011 World Stem Cell Summit in Pasadena, California at 2:30 p.m. PDT on Monday, October 3, 2011.
Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the Company will present at the Second Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference on Thursday, October 6, 2011 at the New York Academy of Medicine in New York City.
CorMedix Inc. (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that on September 15, 2011, the U.S. Food and Drug Administration (the “FDA”) advised CorMedix, that the Center for Drug Evaluation and Research (“CDER”) has been assigned as the lead agency for the pre-market review of Neutrolin®.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials.
GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announces that both its Chief Scientific Officer and its Chairman are to receive academic honors on September 26 and October 21, respectively.
International Stem Cell Corporation (OTCBB: ISCO) today announced that Representative Brian Bilbray recently met with Company executives, including Chairman Kenneth Aldrich, President and Chief Executive Officer Andrey Semechkin, and Senior Vice President Kurt May, to discuss key federal government issues relating to stem cell research. Rep. Bilbray represents California’s 50th congressional district, which includes portions of San Diego’s North County.
Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has initiated dosing in its PEDigree clinical trial where iSONEP™ is being investigated as a treatment for retinal pigment epithelium detachment ("RPE detachment" or "PED").
NanoViricides, Inc. (OTCBB: NNVC) (the "Company") announced that it has filed a request for an automatic extension of the filing date for its Form 10-K Annual Report.
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster presentations and an oral presentation at the upcoming 29th Annual Scientific Meeting of The Obesity Society.
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider and an innovator of the ethnobridging study, today announcedthe publication of the new edition of Accelerating Global Drug Development: The Science and Practice of Ethnobridging.
Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it co-led a $21 million Series C financing for Putney, a Portland, ME-based specialty pharmaceutical company focused on providing high quality, cost-effective generic medicines for pets.
XYTOS, Inc. (OTC: XYTS) previously announced that the company had signed an agreement to list on the German Stock Exchange. After months of submitting all the necessary documents and going through an extensive Due Diligence process XYTOS is very pleased to announce that the company’s Euro Shares will start trading next week on the Frankfurt Stock Exchange under the symbol XY5.
Savanna East Africa, Inc. (PINKSHEETS: NVAE) today announced a corporate update presentation from CEO Randell Torno scheduled for next Thursday, October 6th.
BioLargo, Inc. (OTCBB: BLGO), creator of patented iodine technologies, today announced that the United States Patent and Trademark office had granted BioLargo two additional patents.
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites